JP2018524558A - コロイドペクチンビスマス含有製剤の溶出性の検出方法 - Google Patents
コロイドペクチンビスマス含有製剤の溶出性の検出方法 Download PDFInfo
- Publication number
- JP2018524558A JP2018524558A JP2017558668A JP2017558668A JP2018524558A JP 2018524558 A JP2018524558 A JP 2018524558A JP 2017558668 A JP2017558668 A JP 2017558668A JP 2017558668 A JP2017558668 A JP 2017558668A JP 2018524558 A JP2018524558 A JP 2018524558A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- bismuth
- acid
- dissolution
- colloidal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims abstract description 234
- 229910052797 bismuth Inorganic materials 0.000 title claims abstract description 232
- 239000001814 pectin Substances 0.000 title claims abstract description 111
- 235000010987 pectin Nutrition 0.000 title claims abstract description 111
- 229920001277 pectin Polymers 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 61
- 238000004090 dissolution Methods 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims abstract description 90
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 48
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 40
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 20
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 20
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 20
- 238000000691 measurement method Methods 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 171
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical group O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 47
- 229910017604 nitric acid Inorganic materials 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 238000004040 coloring Methods 0.000 claims description 37
- 239000012488 sample solution Substances 0.000 claims description 30
- 238000010828 elution Methods 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 26
- 238000002835 absorbance Methods 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000007853 buffer solution Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 7
- 230000000112 colonic effect Effects 0.000 claims description 6
- 239000007919 dispersible tablet Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000010227 cup method (microbiological evaluation) Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000011978 dissolution method Methods 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 2
- 239000012738 dissolution medium Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract 1
- 239000012490 blank solution Substances 0.000 description 30
- 239000011550 stock solution Substances 0.000 description 20
- 239000012086 standard solution Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 12
- 238000002798 spectrophotometry method Methods 0.000 description 12
- 239000010453 quartz Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000002372 labelling Methods 0.000 description 9
- 239000000084 colloidal system Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010812 external standard method Methods 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 238000001246 colloidal dispersion Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 3
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 2
- 229960000199 bismuth subgallate Drugs 0.000 description 2
- REKWPXFKNZERAA-UHFFFAOYSA-K bismuth;2-carboxyphenolate Chemical compound [Bi+3].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O REKWPXFKNZERAA-UHFFFAOYSA-K 0.000 description 2
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- RXPAJWPEYBDXOG-UHFFFAOYSA-N hydron;methyl 4-methoxypyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(OC)=CC=N1 RXPAJWPEYBDXOG-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/075—Investigating concentration of particle suspensions by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
【選択図】図1
Description
Claims (12)
- コロイドペクチンビスマス含有製剤の溶出性の検出方法であって、
「中国薬局方2010年版二部付録XC」の溶出性測定法により、コロイドペクチンビスマス含有製剤を、水、pH1.0〜10.0の緩衝溶液、酸溶液である溶出媒体において、30〜150回転/分の回転数で3〜120分間溶解し、溶出液を直接取って、溶出液にプロトン酸解離剤を前記溶出液中の水素イオン濃度が0.8〜1.2mol/Lとなるまで添加し、解離終了後、遠心分離して上澄み液を得、クエン酸又はアスコルビン酸とヨウ化カリウムの発色溶液を加えて発色させ、供試品溶液を得て、380〜470nm波長で前記供試品溶液の吸光度を測定し、同じ条件下で濃度が既知のビスマス対照品溶液の吸光度と比較して、ビスマス換算によるコロイドペクチンビスマス溶出量を計算する溶出性の検出方法。 - 前記コロイドペクチンビスマス含有製剤は、錠剤、分散性錠剤、腸溶性錠剤、結腸溶性錠剤、カプセル、ソフトカプセル、腸溶性カプセル、結腸溶性カプセル、顆粒剤、ドリッピングピル、マイクロカプセル又は乾燥懸濁剤等の全ての適切な剤型を含む、コロイドペクチンビスマスを含有するいずれかの単方又は復方製剤であることを特徴とする請求項1に記載の方法。
- 前記緩衝溶液は、pH1.0〜10.0の酢酸塩緩衝溶液、フタル酸塩緩衝溶液、リン酸塩緩衝溶液又はホウ酸塩緩衝溶液であることを特徴とする請求項1に記載の方法。
- 前記酸溶液は0.005〜0.1mol/L塩酸溶液であることを特徴とする請求項1に記載の方法。
- 前記溶出性測定法は、「中国薬局方2010年版二部付録XC」におけるバスケット法(basket method)、パドル法又は小カップ法(small cup method)のいずれか1つであることを特徴とする請求項1に記載の方法。
- 前記プロトン酸解離剤は硝酸、塩酸又は硫酸であることを特徴とする請求項1に記載の方法。
- 前記発色溶液は、クエン酸又はアスコルビン酸とヨウ化カリウムの水溶液又は0.2〜2mol/L硝酸溶液であることを特徴とする請求項1に記載の方法。
- 前記発色溶液には、クエン酸又はアスコルビン酸0.5wt%〜10wt%、ヨウ化カリウム2.5wt%〜25wt%が含まれることを特徴とする請求項7に記載の方法。
- 前記所定量の原料、添加剤にバインダーを添加して、湿式造粒した後に打錠して得ることを特徴とする請求項7に記載のコロイドビスマスペクチンを含有する分散製剤の製造方法。
- 前記ビスマス対照品溶液は、金属ビスマスを硝酸で溶解した後、水を加えて希釈して、発色溶液を添加したビスマス対照品溶液であることを特徴とする請求項1に記載の方法。
- 前記プロトン酸解離剤で解離した溶出液を、7000〜10000回転/分の回転数で、5〜15分間遠心分離することを特徴とする請求項1に記載の方法。
- 399nm、433nm、463nmのうちのいずれか1つの波長を用い、単波長法により測定し、又はそのうちの任意の2つの波長を用い、二波長法により測定することを特徴とする請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510348307.5 | 2015-06-23 | ||
CN201510348307.5A CN104897668B (zh) | 2015-06-23 | 2015-06-23 | 用于检测含胶体果胶铋制剂溶出度的方法 |
PCT/CN2016/083740 WO2016206524A1 (zh) | 2015-06-23 | 2016-05-27 | 用于检测含胶体果胶铋制剂溶出度的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018524558A true JP2018524558A (ja) | 2018-08-30 |
JP6538880B2 JP6538880B2 (ja) | 2019-07-03 |
Family
ID=54030469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017558668A Active JP6538880B2 (ja) | 2015-06-23 | 2016-05-27 | コロイドペクチンビスマス含有製剤の溶出性の検出方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180017496A1 (ja) |
EP (1) | EP3315946B1 (ja) |
JP (1) | JP6538880B2 (ja) |
CN (1) | CN104897668B (ja) |
AU (1) | AU2016284237B2 (ja) |
WO (1) | WO2016206524A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104897668B (zh) * | 2015-06-23 | 2016-08-24 | 山西振东安特生物制药有限公司 | 用于检测含胶体果胶铋制剂溶出度的方法 |
CN104880428B (zh) * | 2015-06-23 | 2016-07-06 | 山西振东安特生物制药有限公司 | 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法 |
CN108107038A (zh) * | 2017-10-31 | 2018-06-01 | 江西医学高等专科学校 | 一种快速检测夏天无胶囊中总生物碱类成分溶出度的方法 |
CN109991184B (zh) * | 2018-01-02 | 2022-01-21 | 山西振东安特生物制药有限公司 | 胶体果胶铋或含胶体果胶铋制剂中游离铋的检测方法 |
CN111089821A (zh) * | 2018-10-23 | 2020-05-01 | 武汉武药科技有限公司 | 一种艾曲泊帕片的溶出度测定方法和应用 |
CN109633000A (zh) * | 2018-12-25 | 2019-04-16 | 湖北丽益医药科技有限公司 | 枸橼酸铋钾及其制剂中游离铋的检测方法 |
CN110389105B (zh) * | 2019-06-25 | 2022-03-15 | 湖南九典制药股份有限公司 | 一种胶体果胶铋中游离铋的检测方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1137991A (ja) * | 1997-07-16 | 1999-02-12 | Mitsubishi Gas Chem Co Inc | 過酸化水素の分析用発色剤及び簡易定量法 |
JP2009520838A (ja) * | 2005-12-02 | 2009-05-28 | ペイシュー リン, | ヒアルロン酸ビスマス、その調製方法及び使用 |
CN102507381A (zh) * | 2011-10-09 | 2012-06-20 | 于学敏 | 胶体果胶铋化合物及其药物组合物的质量检测方法 |
CN102590123A (zh) * | 2012-02-17 | 2012-07-18 | 长治学院 | 枸橼酸铋钾药物中铋含量的检测方法 |
CN102391389B (zh) * | 2011-08-12 | 2013-06-12 | 于学敏 | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1205012A1 (ru) * | 1984-04-09 | 1986-01-15 | Физико-химический институт им.А.В.Богатского | Способ определени висмута в сурьме |
US6762841B1 (en) * | 2000-02-22 | 2004-07-13 | Spectraalliance, Inc. | Method of performing spectral analysis in a pharmaceutical dissolution process |
US20040132816A1 (en) * | 2003-01-06 | 2004-07-08 | Liao Medical Corporation | Lipid metabolism and fructus crataegus |
US20070225194A1 (en) * | 2004-08-20 | 2007-09-27 | Cao Group, Inc. | Household and Industrial Cleaners and Methods for Making and Using Them |
US20060083824A1 (en) * | 2004-10-20 | 2006-04-20 | Pbm Products Llc | Nutritional supplements for glucose intolerant individuals |
TW200715961A (en) * | 2005-10-28 | 2007-05-01 | Sinon Corp | Herbicide composition |
CN101008610B (zh) * | 2006-11-21 | 2010-05-19 | 宁夏启元药业有限公司 | 山楂精降脂分散片的溶出度测定方法 |
GB2446166B (en) * | 2007-01-29 | 2010-05-12 | Teraview Ltd | A pharmaceutical analysis method and apparatus |
US20100267049A1 (en) * | 2009-04-15 | 2010-10-21 | Rutter William J | Diagnostic devices and related methods |
CN105675800A (zh) * | 2010-12-22 | 2016-06-15 | 3M创新有限公司 | 包括中和剂的灭菌指示器以及方法 |
KR20140000710A (ko) * | 2011-01-24 | 2014-01-03 | 바스프 에스이 | 구강 건강 증진 조성물 |
US9144224B2 (en) * | 2013-02-20 | 2015-09-29 | Quality Logistics Systems, Inc. | Animal litter having light-weight composition and a property of detecting animal health conditions from contact with animal urine |
WO2015118885A1 (ja) * | 2014-02-07 | 2015-08-13 | 株式会社Nbcメッシュテック | 細菌性皮膚病用殺菌組成物 |
CN104147041B (zh) * | 2014-08-17 | 2017-02-22 | 山西振东安特生物制药有限公司 | 一种含胶体果胶铋的分散制剂及其制备方法 |
CN104897668B (zh) * | 2015-06-23 | 2016-08-24 | 山西振东安特生物制药有限公司 | 用于检测含胶体果胶铋制剂溶出度的方法 |
CN104880428B (zh) * | 2015-06-23 | 2016-07-06 | 山西振东安特生物制药有限公司 | 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法 |
EP3454867B1 (en) * | 2016-05-11 | 2021-03-24 | University of Southern California | Fasting mimicking diet (fmd) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases |
US20180003716A1 (en) * | 2016-06-29 | 2018-01-04 | John P. Studdiford | Devices for detection of an analyte in urine and methods of using same |
-
2015
- 2015-06-23 CN CN201510348307.5A patent/CN104897668B/zh active Active
-
2016
- 2016-05-27 WO PCT/CN2016/083740 patent/WO2016206524A1/zh active Application Filing
- 2016-05-27 AU AU2016284237A patent/AU2016284237B2/en active Active
- 2016-05-27 US US15/548,095 patent/US20180017496A1/en not_active Abandoned
- 2016-05-27 JP JP2017558668A patent/JP6538880B2/ja active Active
- 2016-05-27 EP EP16813640.6A patent/EP3315946B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1137991A (ja) * | 1997-07-16 | 1999-02-12 | Mitsubishi Gas Chem Co Inc | 過酸化水素の分析用発色剤及び簡易定量法 |
JP2009520838A (ja) * | 2005-12-02 | 2009-05-28 | ペイシュー リン, | ヒアルロン酸ビスマス、その調製方法及び使用 |
CN102391389B (zh) * | 2011-08-12 | 2013-06-12 | 于学敏 | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 |
CN102507381A (zh) * | 2011-10-09 | 2012-06-20 | 于学敏 | 胶体果胶铋化合物及其药物组合物的质量检测方法 |
CN102590123A (zh) * | 2012-02-17 | 2012-07-18 | 长治学院 | 枸橼酸铋钾药物中铋含量的检测方法 |
Non-Patent Citations (1)
Title |
---|
浙江冶金, 浙江冶金, vol. 第4期, JPN6018044435, 1998, pages 26-31頁 * |
Also Published As
Publication number | Publication date |
---|---|
CN104897668A (zh) | 2015-09-09 |
EP3315946A1 (en) | 2018-05-02 |
WO2016206524A1 (zh) | 2016-12-29 |
AU2016284237B2 (en) | 2019-01-17 |
AU2016284237A1 (en) | 2017-12-21 |
CN104897668B (zh) | 2016-08-24 |
US20180017496A1 (en) | 2018-01-18 |
EP3315946A4 (en) | 2019-02-27 |
JP6538880B2 (ja) | 2019-07-03 |
EP3315946B1 (en) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6538880B2 (ja) | コロイドペクチンビスマス含有製剤の溶出性の検出方法 | |
JP6524260B2 (ja) | コロイドペクチンビスマス又はコロイドペクチンビスマス含有製剤におけるビスマス含有量の測定方法 | |
JP6942263B2 (ja) | コロイドビスマスペクチン又はコロイドビスマスペクチン含有製剤中の遊離ビスマスの測定方法 | |
Kouchak et al. | Preparation and evaluation of taste masking iron suspension: taking advantage of weak cationic exchange resin | |
Aziz et al. | Spectrophotometric determination of mesalazine in pharmaceutical preparations by diazotization and coupling with 2, 6-Dihydroxytoluene as a new coupling agent | |
Ayad et al. | Utility of molybdophosphoric acid in qualitative and quantitative analysis of Sibutramine HCl, Sumatribtan succinate and Lomefloxacine HCl | |
CN113624702B (zh) | 一种雷贝拉唑钠肠溶片的溶出曲线测定方法 | |
CN109498585B (zh) | 一种枸地氯雷他定片剂及其制备方法 | |
CN112114052B (zh) | 一种辛伐他汀片溶出度的测定方法 | |
A Omer et al. | Indirect spectrophotometric methods for the determination of cefadroxil in its pure and pharmaceutical preparations | |
CN112611728A (zh) | 一种新药奥美拉唑咀嚼片的溶出度测定方法 | |
De et al. | Extraction and spectrophotometric determination of cobalt (ii) with 2-thenoyltrifluoroacetone | |
US10350198B2 (en) | Pharmaceutical composition of MEK inhibitor and preparation method thereof | |
CN110389105B (zh) | 一种胶体果胶铋中游离铋的检测方法 | |
Zakhari et al. | Diazotised 4-nitroaniline as a chromogenic reagent for the determination of indole derivatives in certain pharmaceutical preparations | |
CN109991184B (zh) | 胶体果胶铋或含胶体果胶铋制剂中游离铋的检测方法 | |
Marabathuni et al. | Controlled release miglitol microspheres formulation development and evaluation | |
Mohamed et al. | Spectrophotometric determination of peptic ulcer sulfur‐containing drugs in bulk form and in tablets | |
Hammodi | Spectrophotometric Determination of Rantidine-HCl in Pharmaceutical Formulations | |
F Hussein et al. | Spectrophotometric determination of Levo-dopa in pharmaceutical preparation via oxidative coupling organic reaction | |
Said et al. | Methods for micro-and semi-micro determination of thiamine in pharmaceutical preparations | |
CN110987842A (zh) | 一种陈香露白露片中主药次硝酸铋含量的测定方法 | |
CN109481413A (zh) | 一种溶出度高的植物纤维素胶囊 | |
Michael et al. | A Validated Spectrophotometric assay of some proton pump inhibitors using diazotized p-nitroaniline in alkaline medium | |
SALEM et al. | Spectrophotometric Determination of Some Non-Steroidal Anti-Inflammatory Drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190606 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6538880 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |